Increasing hemophilia patient base worldwide especially in developed countries is expected to
drive growth of the hemophilia gene therapy market
High prevalence of hemophilia is increasing demand for sustainable treatment of the disease,
which is projected to drive the market growth over the forecast period. According to the
National Hemophilia Foundation factsheet 2018, hemophilia affected over 400,000 individuals
worldwide. Moreover, according to same source, an estimated 75% of patients suffering from
hemophilia have no access to treatment or receive inadequate treatment. According to the
Centers for Disease Control and Prevention (CDC) report, Hemophilia A occurs in 1 out of 5,000
live male births. It is around four times more common than Hemophilia B. Few effective
treatments available for hemophilia require lifetime infusion of expensive drugs manufactured
through recombinant biotechnology or from human plasma.
For In depth Information Get Sample Copy of this Report @
https://www.coherentmarketinsights.com/insight/request-sample/2480
Key players operating in the global hemophilia gene therapy market include BioMarin
Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical,
Shire PLC Sangamo Therapeutics, Inc., and Freeline Therapeutics.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com